Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 50 years, we’ve delivered thoughtful, effective advice backed by research and real-world experience.
Stay informed with our latest insights.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
The Consumer Financial Protection Bureau increasingly expects institutions to explore less discriminatory alternatives (LDAs) as part of their disparate impact...
Connect with us at conferences, seminars, and webinars.
Kirsten Axelsen moderates the PhRMA-sponsored panel session on HTA system learnings for CMS’ MFP process. For more information on this event, click here.
Dave Duski is a panelist during the session titled “Patent Damages: What is Really at Stake?” There are a variety of different types of damages that can be...
Read our case studies to see the problems we’ve solved and results we’ve delivered.